To the full analysis
Buyback calculator for Sarepta Therapeutics
Sarepta Therapeutics stock: key metrics
SRPTSarepta Therapeutics had an operating margin of −29.9% and a return on invested capital (ROIC) of −37.7% in fiscal 2025.
Margins show how much of revenue is left over, returns on capital how hard the invested money works.
Daily figure as of 13 Nov 2026
Margins
- Gross margin
- Operating margin
- Net margin
Figures as a table
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| 2006 | 100.0% | −28,608.5% | −26,951.8% |
| 2007 | 100.0% | −301.4% | −247.3% |
| 2008 | 100.0% | −129.2% | −112.7% |
| 2009 | 100.0% | −88.2% | −143.1% |
| 2010 | 6.7% | −71.2% | −109.4% |
| 2011 | 23.5% | −76.5% | −4.9% |
| 2012 | −39.1% | −79.6% | −324.9% |
| 2013 | −535.0% | −635.0% | −787.6% |
| 2014 | −864.5% | −1,371.2% | −1,391.7% |
| 2015 | −11,567.5% | −17,572.5% | −17,560.3% |
| 2016 | 97.6% | −4,920.3% | −4,930.2% |
| 2017 | 95.2% | −111.0% | −32.8% |
| 2018 | 88.6% | −114.1% | −120.2% |
| 2019 | 85.1% | −185.3% | −187.8% |
| 2020 | 88.3% | −104.5% | −102.6% |
| 2021 | 86.2% | −65.5% | −59.7% |
| 2022 | 85.0% | −57.5% | −75.4% |
| 2023 | 87.9% | −21.5% | −43.1% |
| 2024 | 83.2% | 11.5% | 12.4% |
| 2025 | 59.9% | −29.9% | −32.5% |
Returns on capital
- ROE
- ROIC
- ROA
Figures as a table
| Year | ROE | ROIC | ROA |
|---|---|---|---|
| 2006 | −82.4% | −69.1% | −76.0% |
| 2007 | −100.0% | −78.5% | −70.3% |
| 2008 | −100.0% | −91.8% | −93.8% |
| 2009 | −100.0% | −54.5% | −41.9% |
| 2010 | 200.0% | no data | −70.0% |
| 2011 | −7.5% | no data | −4.3% |
| 2012 | −98.1% | −29.3% | −59.2% |
| 2013 | −45.3% | −37.4% | −38.4% |
| 2014 | −54.8% | −40.9% | −46.0% |
| 2015 | −100.0% | −72.4% | −80.4% |
| 2016 | −79.4% | −72.8% | −63.0% |
| 2017 | −6.4% | −17.1% | −3.9% |
| 2018 | −35.1% | −20.2% | −22.0% |
| 2019 | −87.4% | −36.7% | −39.2% |
| 2020 | −72.7% | −21.5% | −18.6% |
| 2021 | −45.1% | −13.7% | −13.3% |
| 2022 | −100.0% | −16.3% | −22.5% |
| 2023 | −62.4% | −8.1% | −16.4% |
| 2024 | 15.4% | 18.8% | 5.9% |
| 2025 | −62.5% | −37.7% | −21.3% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 9 May 2025)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.